Ventricular arrhythmias in Chronic Chagas' Myocardiopathy: A case report and brief review of different antiarrhythmic strategies

Manzano‐Fernández, Sergio; Saura, Daniel; Pastor, Patricia; Pastor, Francisco; Morena, Gonzalo de la; Valdés‐Chávarri, Mariano

doi:10.1016/j.ijcard.2008.05.064

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 27 , 36 Amiodarone is used as the preferred antiarrhythmic agent in these patients. 7 , 11 , 27 , 28 , 37 One study reported that treatment of CCM with ICDs and amiodarone resulted in a 95% relative risk reduction in SCD (p=0.006) and a 72% reduction in all-cause mortality (p=0.007). 37 …”

Section: Discussionmentioning

confidence: 99%

Chagas Disease-induced Sudden Cardiac Arrest

Neeki¹,

Park²,

Sandhu³

et al. 2017

CPC-EM

View full text Add to dashboard Cite

Sudden cardiac death (SCD) is the most common cause of death in patients with Chagas disease (ChD). There are over 300,000 ChD-infected individuals living in the United States, of whom 10–15% have undiagnosed Chagas cardiomyopathy (CCM). CCM patients have a higher risk of SCD compared to non-CCM patients, although early and appropriate treatment of CCM patients can result in a 95% relative risk reduction of SCD. Emergency physicians have a unique opportunity to improve outcomes among these patients by becoming more vigilant in recognizing the signs and symptoms of CCM in patients who present in sudden cardiac arrest. We report the case of a patient presenting to the emergency department with pulseless ventricular tachycardia and an undiagnosed history of CCM.

show abstract

Section: Discussionmentioning

confidence: 99%

Chagas Disease-induced Sudden Cardiac Arrest

Neeki¹,

Park²,

Sandhu³

et al. 2017

CPC-EM

View full text Add to dashboard Cite

show abstract

Device therapy in Chagas disease heart failure

Bestetti¹,

Cardinalli-Neto

2012

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Chagas disease is the principal cause of chronic heart failure in areas where the disease is endemic. The medical treatment is the same recommended for non-Chagas disease patients. There is no evidence-based medicine support for device therapy in Chagas disease heart failure. Cardiac resynchronization therapy is recommended for Chagas disease heart failure patients with intraventricular conduction disturbances, mainly for those with left bundle branch block, and in advanced congestive heart failure refractory to targeted medical treatment, although this therapy is still polemic in Chagas disease heart failure. Implantable cardioverter-defibrillator (ICD) therapy is indicated to Chagas disease patients with left ventricular ejection fraction <30% for primary prevention of sudden cardiac death. ICD therapy is offered to patients for secondary prevention of sudden cardiac death. Patients with moderate left ventricular dysfunction and inducible arrhythmia at electrophysiological testing should receive ICD therapy.

show abstract

Ventricular arrhythmias in Chronic Chagas' Myocardiopathy: A case report and brief review of different antiarrhythmic strategies

Cited by 2 publications

References 11 publications

Chagas Disease-induced Sudden Cardiac Arrest

Chagas Disease-induced Sudden Cardiac Arrest

Device therapy in Chagas disease heart failure

Contact Info

Product

Resources

About